大唐药业(836433) - 投资者关系活动记录表

Group 1: Investor Relations Activity - The investor relations activity was held on July 11, 2025, from 16:00 to 18:00 via an online platform [3] - Participants included the company's Vice Chairman and Secretary of the Board, Ms. Sun Yali, and Financial Officer, Mr. Wu Bo [3] Group 2: Research and Development Progress - The company has established a three-tiered R&D system with 2 national projects, 3 regional key projects, and 3 municipal key projects [4] - The company is enhancing its intellectual property protection and has formed partnerships with several universities and research institutions to advance the modernization of traditional Chinese medicine [4] Group 3: Future Planning and Strategy - The company is focusing on a "123" overall development strategy centered on traditional Mongolian medicine, with a focus on specialty drugs and health products [5] - The strategy includes integrating financial capital, marketing resources, and R&D efforts to support sustainable growth [5] Group 4: Product Development Update - The company completed the filing for the "An Gong Niu Huang Wan" product on February 7, 2024, with modifications to its formula [6] - The financial impact of this product on the company's results remains uncertain, and investors are advised to be cautious [6] Group 5: Financial Performance - The company plans to disclose its half-year report on August 27, 2025, which will provide insights into its operational performance [8]